In this article
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients
The Food and Drug Administration has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) as a way to treat GEP-NETs in kids 12 years and older who are positive for the somatostatin receptor (SSTR). GEP-NETs can be in the foregut, midgut, or hindgut. Permission for the use of Lutetium Lu 177 dotatate in adults was granted in 2018.
This marks the initial approval by the FDA of a radioactive medicine, often known as a radiopharmaceutical, for children aged 12 and above who have SSTR-positive GEP-NETs.
Efficacy and Safety
The approval was granted after evaluating pharmacokinetic (PK), dosimetry, and safety data from the ongoing international study called NETTER-P (NCT04711135). This study focuses on lutetium Lu 177 dotatate and its effectiveness in treating adolescent patients with locally advanced/inoperable or metastatic SSTR-positive GEP-NETs or pheochromocytoma/paraganglioma (PPGL). The study is open-label and single-arm, conducted at multiple centers.
The approval was also granted based on the extrapolation of efficacy results observed in the NETTER-1 (NCT01578239) trial. This clinical trial was a randomized, multicenter, open-label, active-controlled study involving 229 patients with locally advanced/inoperable or metastatic SSTR-positive midgut carcinoid tumors. The findings from this trial provided additional support for the original approval of lutetium Lu 177 dotatate in adult patients.
The safety of the treatment was assessed in a total of 9 pediatric patients in the NETTER-P study, out of which 4 patients had GEP-NETs. The radiation doses that specific organs absorbed and the occurrence of any unfavorable effects after the initial treatment cycle were the main metrics of interest. As an extra outcome measure, the study looked at any bad reactions that happened right away after lutetium Lu 177 dotatate was given. The adverse reaction profile found in the NETTER-P study was comparable to that observed in the adult population.
The suggested dosage for lutetium Lu 177 dotatate is 7.4 GBq (200 mCi) per 8 weeks (± 1 week) for a total of 4 treatments. Administer premedications and concurrent drugs according to the prescribed guidelines. An obligation was issued after the marketing phase to evaluate the enduring safety of lutetium Lu 177 dotatate in teenagers.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.